Regulatory documentary assessment

Facility permission must be considered separately from clinician authority and controlled-herb permissions.

Evidence of current licence and actual scope; no all-in-one cannabis clinic licence.

Applicable permissions and current scope must be verified by the regulator.

Document-readiness review only. GACP is not cultivation instruction, an export licence or a certificate issued by us.

Provide applicable authority/certification evidence for human verification; no certifications are assumed.

Confirm exact legal form. ONCB leaf permit pathways and FDA product pathways are separate.

Applicability depends on product and current agency determination.

General regulatory feasibility only; no enabled commercial export or shipment workflow.

Exact destination and competent authority are required. Thailand authorization never implies destination permission.

Only if applicable to the exact classified case, never presumed for every export.

Collect only general institutional enquiry and existing authorization evidence for human eligibility review; no sale/export permit checklist.

FDA's 9 June 2025 clarification does not authorize ordinary medical-purpose use under that framework; specified official/analysis/medical-scientific research purposes may be considered. Confirm current applicability.